Contents

	Page No.
List of Abbreviations and Symbols	i
List of Figures	v
List of Tables	ix
Preface	x
1. Introduction	**01- 06**
2. Literature review	**07- 48**
2.1 Overview of Hepatitis	07
2.2 Geographical distribution/epidemiology	08
2.3 The Hepatitis B virus	09
2.4 Hepatitis B virus replication	11
2.5 Hepatitis B virus Transmission	16
2.6 Clinical aspects of Hepatitis B virus	18
2.7 Immune pathogenesis of Hepatitis B virus infection	22
2.8 Mechanisms of Hepatitis B virus clearance	27
2.9 Diagnostics of Hepatitis B virus infection	27
2.10 Polymer-based vaccination	31
2.11 Delivery of therapeutic molecules	33
2.12 Polymeric nanoparticles for antigen delivery & adjuvants	35
2.13 Distribution of polymeric nanoparticles	37
2.14 Aspects of immune response	40
2.15 Nanoparticles: advantages and disadvantages	41
2.16 Route of administration of Hepatitis B vaccine	43
2.17 Animal models for Hepatitis B	46
3. Objective and plan of work	**50- 52**
4. Materials and methods	**53- 99**
4.1 Materials	54
4.2 Methods	56
4.2.1 Preformulation study	56
4.2.2 Formulation of antigen HBsAg loaded polymeric nanoparticles	59
4.2.3 *In-vitro* characterization of polymeric HBsAg loaded nanoparticles	66
4.2.4 Surface characterization	67

4.2.5 *In-vitro* release of HBsAg from nanoparticles 68
4.2.6 Structural integrity of HBsAg loaded nanoparticles 71
4.2.7 *In-vitro* cellular uptake study of nanoparticles 72
4.2.8 Haemocompatibility studies 73
4.2.9 Stability study 75
4.2.10 Selection of route of administration in BALB/c mice 76
4.2.11 *In-vivo* cellular internalization study 79
4.2.12 Immunological characterization and measurement of antibody levels 80
4.2.13 *In-vivo* lymphocyte and T cells proliferation study 83
4.2.14 Assessment of immunological parameter in Humanized Xenograft model 86
5. Results and discussion **101-157**
5.1 Preformulation study 101
5.2 Formulation of antigen HBsAg loaded polymeric nanoparticles 102
5.3 *In-vitro* characterization of polymeric HBsAg loaded nanoparticles 116
5.4 Surface characterization 118
5.5 *In-vitro* release of HBsAg from nanoparticles 121
5.6 Structural integrity of HBsAg loaded nanoparticles 124
5.7 *In-vitro* cellular uptake study of nanoparticles 126
5.8 Haemocompatibility studies 130
5.9 Stability study 134
5.10 Selection of route of administration in BALB/c mice 135
5.11 *In-vivo* cellular internalization study 139
5.12 Immunological characterization and measurement of antibody levels 140
5.13 *In-vivo* lymphocyte and T cells proliferation study 145
5.14 Assessment of immunological parameter in Humanized Xenograft model 148
6. Conclusion **159-160**
7. References **161-188**
8. List of publications **-----**

Contents